- Home
- LPTX vs TARA Comparison
LPTX vs TARA Comparison
Compare LPTX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- TARA
- Stock Information
- Founded
- LPTX 2011
- TARA N/A
- Country
- LPTX United States
- TARA United States
- Employees
- LPTX N/A
- TARA N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPTX Health Care
- TARA Health Care
- Exchange
- LPTX Nasdaq
- TARA Nasdaq
- Market Cap
- LPTX 119.6M
- TARA 126.5M
- IPO Year
- LPTX N/A
- TARA N/A
- Fundamental
- Price
- LPTX $0.38
- TARA $3.05
- Analyst Decision
- LPTX Buy
- TARA Strong Buy
- Analyst Count
- LPTX 2
- TARA 7
- Target Price
- LPTX $8.00
- TARA $20.67
- AVG Volume (30 Days)
- LPTX 321.1K
- TARA 255.2K
- Earning Date
- LPTX 08-11-2025
- TARA 08-05-2025
- Dividend Yield
- LPTX N/A
- TARA N/A
- EPS Growth
- LPTX N/A
- TARA N/A
- EPS
- LPTX N/A
- TARA N/A
- Revenue
- LPTX N/A
- TARA N/A
- Revenue This Year
- LPTX N/A
- TARA N/A
- Revenue Next Year
- LPTX N/A
- TARA N/A
- P/E Ratio
- LPTX N/A
- TARA N/A
- Revenue Growth
- LPTX N/A
- TARA N/A
- 52 Week Low
- LPTX $0.22
- TARA $1.60
- 52 Week High
- LPTX $4.79
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- LPTX 46.09
- TARA 41.66
- Support Level
- LPTX $0.38
- TARA $3.12
- Resistance Level
- LPTX $0.44
- TARA $3.24
- Average True Range (ATR)
- LPTX 0.04
- TARA 0.18
- MACD
- LPTX -0.00
- TARA -0.00
- Stochastic Oscillator
- LPTX 22.52
- TARA 14.81
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).